Drugs & Diagnostics for Tropical Diseases

biopharmadive | November 28, 2017

Industry Pulse aims to complement BioPharma Dive’s daily news coverage with a data-driven look at a few of the top stories from the previous quarter. This edition focuses on biopharma's endless quest to reinvent itself with new drugs and new revenue streams....

biopharmadive | December 20, 2017

Perpetual partners Biogen Inc. and Ionis Pharmaceuticals Inc. have entered another research collaboration that aims to their portfolio of spinal muscular atrophy (SMA) treatments beyond Spinraza. The collaboration will focus on identifying antisense oligonucleotide drug candidates for the rare muscular disease, with Ionis responsible for leading and funding the earliest stages of drug development. Once the California-based biotech has discovered a potential candidate, Biogen takes over. The ulti...

biopharmadive | January 08, 2018

Clinical-stage biotech Zafgen, Inc. is looking again at rare diseases, selecting ZGN-1258 for the treatment of rare or orphan metabolic diseases, including Prader-Willi syndrome, sending its shares up around 8% on Friday. Work to support an investigational new drug application is under way, with a Phase 1 trial planned by the end of 2018. Zafgen will also begin a global Prader-Willi syndrome natural history study mid-2018, to add to the limited information available on the medical and clinical h...

ScienceDaily | March 13, 2018

"This not only advances our understanding of how the body responds to cold, but could lead to new ways to control the amount of brown fat in the body, which has links to obesity, diabetes and fatty liver disease," says senior author Ronald Evans, Howard Hughes Medical Institute investigator and holder of Salk's March of Dimes Chair in Molecular and Developmental Biology....